U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drug Shortages

FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | Contact Us | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages

Start Over | Back to Previous Screen

Moxetumomab pasudotox-tdfk (Lumoxiti) Injection
Status: Discontinuation
»Therapeutic Categories: Oncology

AstraZeneca AB (AstraZeneca) (New 01/10/2023)

Company Contact Information:
800-236-9933

Presentation Posting Date Related Information
1 mg vial (NDC 0310-4700-01) 01/10/2023 The planned permanent discontinuation of moxetumomab pasudotox-tdfk) for injection from the U.S. market is August 31, 2023.
Dear Healthcare Provider Letter
Back to Top